Ptc Therapeutics, Inc.

Other

Thomas W Davis

Liangxian Cao

Young-Choon Moon

Marla L Weetall

Langdon Miller

Soongyu Choi

Hongyan Qi

Samit Hirawat

William Jospeh Lennox

Nadiya Sydorenko

Donald Thomas Corson

Harry H Miao

Seongwoo Hwang

Richard Gerald Wilde

Steven David Paget

Hongyu Ren

Chang-Sun Lee

Christopher Robert Trotta

Charles Romfo

Ramil Y Baiazitov

Nadarajan Tamilarasu

Wu Du

Ronggang Liu

Neil Gregory Almstead

Jeffrey Allen Campbell

Peter Seongwoo Hwang

Zhengxian Gu

Jason D Graci

Daniel J Medina

Tamil Arasu

Melissa L Dumble

Jaime A Eberle-Singh

Marites A Rafanan

Kenneth P Olive

William Joseph Lennox

Maria L Weetall

Don Corson

Jeff Campbell

William Lennox

A method for treating pancreatic cancer in a subject in need thereof comprising, administering to the subject an effective amount of a tubulin polymerization inhibitor compound is described herein. More particularly, a method for treating pancreatic ductal adenocarcinoma in a subject in need thereof comprising, administering to the subject an effective amount of a substituted reverse pyrimidine tubulin polymerization inhibitor compound alone or in combination with other chemo-therapeutic agents is described herein.

Method for treating pancreatic cancer

Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.

Substituted reverse pyrimidine Bmi-1 inhibitors

Compounds, such as compounds of Formula (I), that selectively inhibit pathological production of human vascular endothelial growth factor (VEGF) and compositions comprising such Compounds are described. Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of reducing VEGF using such Compounds and methods for treating cancer and non-neoplastic conditions involving the administration of such Compounds. Further described are methods of inhibiting viral replication or the production of viral RNA or DNA or viral protein using such Compounds and methods for treating viral infections involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments. 

Methods for treating cancer and non-neoplastic conditions

Methods for treating prostate cancer involving the administration of a compound that selectively inhibits pathological production of human vascular endothelial growth factor (VEGF) are described. Methods for treating benign prostatic hyperplasia involving the administration of a compound that selectively inhibits pathological production of human VEGF are also described. The compound may be administered as a single-agent therapy or in combination with one or more additional therapies to a human in need of such treatment.

Methods for treating prostate conditions

Methods for treating Kaposi's sarcoma involving the administration of a compound that selectively inhibits pathological production of human VEGF are described. The compound can be administered as a single-agent therapy or in combination with one or more additional therapies to a human in need of such treatment.

Methods for treating Kaposi sarcoma

Compounds having Formula I: wherein the variables Ar, Ar, R, Rand Rare defined herein, pharmaceutical compositions, and methods of using such compounds or compositions for inhibiting Bmi-1 expression.

BMI-1 protein expression modulators

The methods described herein provide nucleic acid constructs and screening methods for identifying and validating compounds for use in the treatment of cancer, wherein the compounds down-regulate the post-transcriptional expression of Bmi-1.

Methods for screening for compounds for treating cancer

In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the treatment of solid tumor cancer, and in reducing plasma and/or tumor VEGF levels, are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the treatment of cancer, and the reduction of plasma and/or tumor VEGF levels, using the compounds of the invention.

Carboline derivatives useful in the inhibition of angiogenesis

In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and compositions, and methods for the administration and use of those compounds. provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the treatment of solid tumor cancer, and in reducing serum, plasma, and/or tumor VEGF levels, are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the treatment of cancer, and the reduction of plasma and/or tumor VEGF levels, using the compounds of the invention.

Administration of carboline derivatives useful in the treatment of cancer and other diseases

In accordance with the present invention, methods for inhibiting the translation of VEGF and methods for decreasing VEGF level by inhibiting VEGF translation are provided. In another aspect of the invention, compounds that inhibit the 5'-UTR-dependent translation of VEGF and methods for identifying such compounds are provided.

Inhibition of VEGF translation

Carboline derivatives useful in the treatment of cancer

A system for cleaning litter in a poultry house by removing caked litter while leaving uncaked litter. The system comprises a separator that connects and disconnects to the front bucket of a skid-steer loader while the operator remains seated. The separator and bucket couple via a bucket and separator coupling. One coupling comprises two spaced apart parallel arms that insert into corresponding sleeves that form the other coupling. Connecting requires aligned forward loader movement with the separator on the ground while disconnecting requires reverse loader movement. The separator comprises a chassis supporting a blade that forces litter into the separator. A plurality of spikes on a rotating reel forcefully break the entering litter into smaller pieces as an integral ramp feeds the litter onto an upwardly moving conveyor. Several perforations in the plates comprising the conveyor permit uncaked litter to fall through onto a return chute while caked litter is retained by a plate lip until being deposited in the bucket. The separator is powered by a hydraulic motor assembly employing a quick-coupling split shaft with automatically mating halves. When removing caked litter, the operator drives the loader through the house while pushing the separator to sift the litter. When the bucket gets full, the operator disconnects the separator and dumps the bucket. The separator is then reconnected to the loader bucket to continue cleaning.

Apparatus and method for removing caked litter from a poultry facility

Ladder attached paint can support

Growing community of inventors

South Orange, NJ, United States of America

Thomas W Davis